Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative. It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. The relative importance of each of these mechanisms in determining clinical response to rituximab treatment remains a matter of conjecture. Thus, the role of various resistance pathways, some documented in experimental systems and others still hypothetical, remains uncertain. Resistance could potentially be mediated by alterations in CD20 expression or signaling, elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity. As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rituximab is an anti-CD20 mAb that depletes B cells by inducing apoptosis (49).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [49]
In the citing paper
“Rituximab (RTX) is a chimeric mouse/human monoclonal antibody targeting CD20 present in pre‐B and mature B cells except plasma cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [81]
In the citing paper
“It depletes B cells by inducing apoptosis, antibody dependent cell-mediated cytotoxicity and complement dependent cytotoxicity, thereby limiting antibody production and epitope presentation via MHC class II to TH cells (81).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [81]
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755 · cited 5×
“Rituximab efficacy and scope of clinical resistance Rituximab is approved for use in refractory or relapsed indolent NHL, based on a pivotal trial demonstrating a response rate of over 50% in such patients (McLaughlin et al., 1998).”
BackgroundInfluentialFisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149 · cited 1×
“These are potentially curable with combination chemotherapy, but if not cured usually are fatal within 2–3 years (Fisher et al., 1993).”
BackgroundDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900 · cited 2×
“In a small group of patients with previously untreated follicular lymphoma who received rituximab, response rates and molecular complete remission rates were higher in 10 of the 49 patients homozygous for the FcgRIIIA with V158, than those who had either one or two copies of FcgRIIIA with F158 (Cartron et al., 2002).”
BackgroundRavetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,283 · cited 5×
“The inhibitory FcgRIIB and KIR signal via ITIM domains that are substrates for src-family tyrosine kinases and that in turn activate PIP3 phosphatase (SHIP) for FcgRIIB or tyrosine phosphatase (SHP-1, -2) for KIR (Ravetch and Lanier, 2000).”
BackgroundInfluentialArmitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,251 · cited 1×
“…with cells indistinguishable from chronic lymphocytic leukemia, and marginal zone- or mucosa-associated NHL. Patients with these indolent NHL have a median survival of approximately 10 years (Armitage and Weisenburger, 1998), but the disease is considered incurable with current therapeutic options.”
BackgroundKeating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948 · cited 2×
“In CLL, a disease in which the cells have low CD20 levels and a low response rate to standard dose and schedule rituximab (375mg/m2 weekly 4), higher and repeated doses did lead to higher response rates, although these tend to be short lived (Byrd et al., 2001; Keating et al., 2002b).”
BackgroundKoene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711 · cited 1×
“A dimorphism exists in which residue 158 of FcgRIIIA can be either valine, with stronger binding to IgG1, or phenylalanine with weaker binding (Koene et al., 1997; Wu et al., 1997).”
BackgroundAnderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687 · cited 2×
“Furthermore, if CD20 expression alone determined rituximab responsiveness, then one would expect development of CD20-negative relapses after rituximab treatment, and this circumstance has rarely been reported, at least for indolent lymphoma (Davis et al., 2000).”
BackgroundWitzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651 · cited 2×
“In patients refractory to rituximab, overall response rate to the radioimmunotherapy was similar to that of patients who had not previously received rituximab (Witzig et al., 2002a).”
BackgroundResultGolay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604 · cited 7×
“A recent report suggests, based on data with nonsaturating levels of anti-CD20, that an overall assessment of the levels of both CD20 and the complement inhibitory proteins can predict in vitro sensitivity to rituximab-mediated CDC, and that this may correlate with clinical response (Manches et al., 2003).”
BackgroundInfluentialApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512 · cited 2×
“This concept is most clearly illustrated by data for the monoclonal anti-CD52 antibody Campath- Oncogene 1H, found to be much more efficient at clearing NHL cells from blood and marrow than from lymph nodes, leading to studies of this agent in CLL (Osterborg et al., 1997).”
BackgroundByrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508 · cited 1×
“In CLL, a disease in which the cells have low CD20 levels and a low response rate to standard dose and schedule rituximab (375mg/m2 weekly 4), higher and repeated doses did lead to higher response rates, although these tend to be short lived (Byrd et al., 2001; Keating et al., 2002b).”
BackgroundEvasion of innate immunity by parasitic protozoa
Sacks, D., & Sher, A. (2002) · Nature Immunology · doi:10.1038/ni1102-1041 · Cited by 433
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428 · cited 8×
“A recent report suggests, based on data with nonsaturating levels of anti-CD20, that an overall assessment of the levels of both CD20 and the complement inhibitory proteins can predict in vitro sensitivity to rituximab-mediated CDC, and that this may correlate with clinical response (Manches et al., 2003).”
BackgroundInfluentialRituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma
Hainsworth, J. D., Litchy, S., Burris, H. A., Scullin, D. C., Corso, S. W., Yardley, D. A., Morrissey, L., & Greco, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.674 · Cited by 416 · cited 3×
“Owing to its efficacy and tolerability, trials of rituximab as induction therapy are underway and preliminary results suggest higher responses than in relapsed patients (Colombat et al., 2001; Hainsworth et al., 2002), although ultimately improved survival is the critical end point.”
BackgroundResultInfluentialComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390 · cited 2×
“It appears that the ability of CD20 to move into lipid rafts is a requirement for CDC to occur (Cragg et al., 2003).”
BackgroundSignaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385 · cited 2×
“Inhibitor studies indicate that this occurs via src-family kinases (Shan et al., 2000).”
BackgroundIn vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372 · cited 2×
“In vitro testing of cells from patients has correlated CD20 levels with sensitivity to rituximab-mediated CDC in some reports (Golay et al., 2001; Bellosillo et al., 2001), but not others (Manches et al., 2003).”
BackgroundPiro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367 · cited 2×
“Rituximab-mediated apoptosis is thought to be a consequence of caspase-3 activation, and recent data from patients with CLL support this concept (Byrd et al., 2002), whereas the FAS ligand/FAS death pathway does not appear to be necessary.”
BackgroundVose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 359 · cited 1×
“Similar response rates have been reported for a 131I-labeled murine CD20 antibody (Vose et al., 2000).”
BackgroundBubien, J. K., Zhou, L. J., Bell, P. D., Frizzell, R. A., & Tedder, T. F. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.5.1121 · Cited by 355 · cited 1×
“CD20 can act as a calcium channel (Bubien et al., 1993), either directly or by binding to or activating a calcium channel.”
BackgroundCD20‐mediated apoptosis: signalling through lipid rafts
Deans, J. P., Li, H., & Polyak, M. J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01495.x · Cited by 233 · cited 1×
“Another means of clustering is the finding that after CD20 is bound, it rapidly redistributes into a cell membrane fraction called a lipid raft (Deans et al., 1998, 2002), which may aid in signal activation through the src-family tyrosine kinases.”
BackgroundThe B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
Tedder, T. F., Boyd, A. W., Freedman, A. S., Nadler, L. M., & Schlossman, S. F. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.973 · Cited by 226
Hofmeister, J. K., Cooney, D., & Coggeshall, K. M. (2000) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2000.0287 · Cited by 222 · cited 2×
“The extent of intracellular signal transduction, at least in some systems, can also be affected by the clustering of CD20 (Hofmeister et al., 2000).”
BackgroundPedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219 · cited 1×
“The pleiotropic effects of PLC-g including MAP kinase activation and specifically JNK, ERK and p38MAPK have been implicated in rituximab signaling (Pedersen et al., 2002).”
BackgroundWeng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218 · cited 2×
“In vitro CDC, however, did not correlate with clinical response (Weng and Levy, 2001).”
BackgroundTreon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205 · cited 9×
“A recent report suggests, based on data with nonsaturating levels of anti-CD20, that an overall assessment of the levels of both CD20 and the complement inhibitory proteins can predict in vitro sensitivity to rituximab-mediated CDC, and that this may correlate with clinical response (Manches et al., 2003).”
BackgroundInfluentialBellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205 · cited 1×
“In vitro testing of cells from patients has correlated CD20 levels with sensitivity to rituximab-mediated CDC in some reports (Golay et al., 2001; Bellosillo et al., 2001), but not others (Manches et al., 2003).”
BackgroundDi Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198 · cited 1×
“Also, the nucleoside analog fludarabine, clinically active against CLL and indolent NHL, has been reported to downregulate CD55 and CD59 (Di Gaetano et al., 2001) and this is a potential means by which fludarabineþ rituximab may have beneficial clinical efficacy.”
BackgroundGhetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191 · cited 1×
“…flux may be observed after soluble antiCD20 binds to cells, quantitatively more pronounced signals develop when homodimerized antibody is used (Ghetie et al., 2001) or when antibody is crosslinked by secondary antibody (Cragg et al., 2003) or by cells expressing Fcg receptors (Shan et al.,…”
BackgroundGolay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Harris, N., Jaffe, E., Stein, H., et al. (1994) · Blood · doi:10.1182/blood.v84.5.1361.bloodjournal8451361 · Cited by 159
Bladergroen, B. A., Meijer, C. J. L. M., ten Berge, R. L., Hack, C. E., Muris, J. J. F., Dukers, D. F., Chott, A., Kazama, Y., Oudejans, J. J., van Berkum, O., et al. (2002) · Blood · doi:10.1182/blood.v99.1.232 · Cited by 153 · cited 1×
“Expression of protease inhibitor 9 has now documented the existence of this resistance mechanism (Bladergroen et al., 2002).”
BackgroundRapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151 · cited 1×
“Another means of clustering is the finding that after CD20 is bound, it rapidly redistributes into a cell membrane fraction called a lipid raft (Deans et al., 1998, 2002), which may aid in signal activation through the src-family tyrosine kinases.”
BackgroundKennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141 · cited 1×
“Membrane-attached C3 and C3 fragments could be targets of C3 receptor on effector cells, enhancing cell killing by antibody-dependent cellular cytotoxicity ADCC (see below) (Kennedy et al., 2003).”
BackgroundFriedberg, J. W., Neuberg, D. S., Gribben, J. G., Fisher, D. C., Canning, C. M., Koval, M. A., Poor, C. M., Green, L. M., Daley, J. F., Soiffer, R. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03535.x · Cited by 140 · cited 1×
“Additional clinical trials are in progress (Friedberg et al., 2002).”
DONIN, N., JURIANZ, K., ZIPOREN, L., SCHULTZ, S., KIRSCHFINK, M., & FISHELSON, Z. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2003.02066.x · Cited by 139 · cited 1×
“In addition, a role has been reported for the protein kinases PKC, PKA and MEK in complement resistance of some tumor cells (Donin et al., 2003).”
BackgroundMice carrying a CD20 gene disruption
O’Keefe, T. L., Williams, G. T., Davies, S. L., & Neuberger, M. S. (1998) · Immunogenetics · doi:10.1007/s002510050412 · Cited by 129 · cited 2×
“The role of CD20 in B-cell development remains uncertain, as CD20-deficient mice have normal B cells (O’Keefe et al., 1998).”
BackgroundForan, J. M., Gupta, R. K., Cunningham, D., Popescu, R. A., Goldstone, A. H., Sweetenham, J. W., Pettengell, R., Johnson, P., Bessell, E. M., Hancock, B. W., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01965.x · Cited by 121 · cited 1×
“…and marrow of lymphoma cells, even as assayed by sensitive PCR methods for IgH gene rearrangements or t(14;18), were followed by the realization that even patients with molecular remissions continue to relapse, indicating persistence of lymphoma cells (Foran et al., 2000; Pichert et al., 2001).”
BackgroundKennedy, G., Tey, S., Cobcroft, R., Marlton, P. V., Cull, G., Grimmett, K., Thomson, D. B., & Gill, D. S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03843.x · Cited by 121 · cited 1×
“Recent reports are perhaps suggestive that CD20-negative relapses may develop in aggressive lymphomas (Davis et al., 1999; Foran et al., 2001; Kennedy et al., 2002), but care must be taken to differentiate true CD20 negativity from false-negative results attributable to blocking of labeled CD20…”
BackgroundForan, J. M., Norton, A. J., Micallef, I. N. M., Taussig, D. C., Amess, J. A. L., Rohatiner, A. Z. S., & Lister, T. A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03019.x · Cited by 113 · cited 1×
“Recent reports are perhaps suggestive that CD20-negative relapses may develop in aggressive lymphomas (Davis et al., 1999; Foran et al., 2001; Kennedy et al., 2002), but care must be taken to differentiate true CD20 negativity from false-negative results attributable to blocking of labeled CD20…”
BackgroundDeans, J. P., Kalt, L., Ledbetter, J. A., Schieven, G. L., Bolen, J. B., & Johnson, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22632 · Cited by 105 · cited 1×
“CD20 is associated with a number of protein tyrosine kinases, including lyn, fyn, lck and p75/85 kinase (Deans et al., 1995).”
BackgroundDeans, J. P., Schieven, G. L., Shu, G. L., Valentine, M. A., Gilliland, L. A., Aruffo, A., Clark, E. A., & Ledbetter, J. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.9.4494 · Cited by 98
Harjunpää, A., Wiklund, T. A., Collan, J., Janes, R., Rosenberg, J., Lee, D., Grillo-López, A. J., & Meri, S. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099335 · Cited by 92 · cited 1×
“…antibodies to traditional chemotherapy sanctuary sites, such as brain or testis, which are protected from toxins by physiologic barriers, although one case report detected only very low levels of rituximab in the CSF of a patient with CNS involvement of systemic NHL (Harjunpaa et al., 2001).”
BackgroundPetrie, R. J., & Deans, J. P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.2886 · Cited by 87 · cited 1×
“Of interest is that CD20 associates with the BCR in these lipid rafts (Petrie and Deans, 2002), suggesting that the observed similarities in BCR and CD20 signaling may have a structural basis.”
BackgroundLeonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74
Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?
Selenko-Gebauer, N., Majdic, O., Jaeger, U., Sillaber, C., Stöckl, J., & Knapp, W. (2002) · Journal of Clinical Immunology · doi:10.1023/a:1015463811683 · Cited by 69 · cited 1×
“In vitro studies support such a crosspriming effect (Selenko et al., 2002).”
BackgroundAnalysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
van der Kolk, L., de Haas, M., Grillo-López, A. J., Baars, J. W., & van Oers, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402424 · Cited by 68 · cited 1×
“There have been attempts to upregulate CD20 to try to enhance rituximab efficacy, such as with G- or GM-CSF, but mechanisms other than CD20 upregulation may account for any enhanced effect (Ravetch and Lanier, 2000; van der Kolk et al., 2002).”
BackgroundCzuczman, M. S., Grillo-López, A. J., McLaughlin, P. J., White, C. A., Saleh, M. N., Gordon, L. I., LoBuglio, A., Rosenberg, J., Alkuzweny, B., & Maloney, D. G. (2001) · Annals of Oncology · doi:10.1023/a:1008395214584 · Cited by 67
Human Natural Killer Cell Receptors and Signal Transduction
Campbell, K. S., & Colonna, M. (2001) · International Reviews of Immunology · doi:10.3109/08830180109054413 · Cited by 63 · cited 1×
“Additional activating and inhibitory coligating signals exist and the balance determines NK activity (Campbell and Colonna, 2001).”
BackgroundEmerging information on the use of rituximab in chronic lymphocytic leukemia
Keating, M. J., O'Brien, S. M., & Albitar, M. X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30142 · Cited by 62 · cited 2×
“In CLL, a disease in which the cells have low CD20 levels and a low response rate to standard dose and schedule rituximab (375mg/m2 weekly 4), higher and repeated doses did lead to higher response rates, although these tend to be short lived (Byrd et al., 2001; Keating et al., 2002b).”
BackgroundWintrobe's Clinical Hematology. Vol.1
Bithell, T. C., Lee, G. R., & Foerster, J. (1993) · Cited by 49
CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma
Warren, T. L., Dahle, C. E., & Weiner, G. J. (2000) · Clinical Lymphoma · doi:10.3816/clm.2000.n.005 · Cited by 41 · cited 1×
“Alternative approaches such as enhanced effector cell activity induced by CpG oligonucleotides are also being investigated (Warren et al., 2000).”
BackgroundKoene, H. R., Kleijer, M., Algra, J., et al. (1997) · Blood · doi:10.1182/blood.v90.3.1109.1109_1109_1114 · Cited by 34 · cited 1×
“A dimorphism exists in which residue 158 of FcgRIIIA can be either valine, with stronger binding to IgG1, or phenylalanine with weaker binding (Koene et al., 1997; Wu et al., 1997).”
BackgroundPichert, G., Schmitz, S. H., Hess, U., Cerny, T., Cogliatti, S., Betticher, D. C., Stupp, R., Schmitter, D., Stahel, R. A., & Ghielmini, M. E. G. (2001) · Clinical Lymphoma · doi:10.3816/clm.2001.n.004 · Cited by 6 · cited 1×
“…and marrow of lymphoma cells, even as assayed by sensitive PCR methods for IgH gene rearrangements or t(14;18), were followed by the realization that even patients with molecular remissions continue to relapse, indicating persistence of lymphoma cells (Foran et al., 2000; Pichert et al., 2001).”
Background
Research works printed but not linked: 1
- Witzig TE, Flinn IW, Gordon LI, Emmanouilldes C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA . (2002b). J. Clin. Oncol., 20, 2453–2463. · DOI · Paper page
Cited by
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Metadata
- Authors
- Smith, M. R.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Smith, Mitchell R
- ORCID
- Smith, Mitchell R
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7359-7368
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2088332148
- Cited by
- 835
- References
- 62
- Citations by year
- 2026: 30 · 2025: 45 · 2024: 33 · 2023: 37 · 2022: 49 · 2021: 64 · 2020: 33 · 2019: 37 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 35 · 2014: 28 · 2013: 32 · 2012: 31
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- rituximab, CD20, monoclonal antibodies, follicular non-Hodgkin's lymphoma, drug resistance, apoptosis signaling, complement activation, cell-mediated cytotoxicity, CD20 expression, B-cell lymphoma, mechanism of action
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Antigen-Antibody Reactions, Humans, Radioimmunotherapy, Treatment Outcome, Apoptosis, Antigens, CD20, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.